Form 8-K Iterum Therapeutics plc For: Mar 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy
March 15, 2021 6:21 AM EDTH.C. Wainwright analyst Ed Arce upgraded Iterum Therapeutics (NASDAQ: ITRM) from Neutral to Buy with a price target of $2.50.
The analyst comments "Recent financings provide substantial runway, allowing investor focus to turn to potential FDA approval and launch. We downgraded ITRM last June on an unclear regulatory path forward for sulopenem (it had missed the primary endpoint on two of three Phase 3 trials) and a short cash runway without an ability to commercialize the drug (or a partner), even... More
